https://scholars.lib.ntu.edu.tw/handle/123456789/484060
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | YU-YUN SHAO | en_US |
dc.contributor.author | Lin H. | en_US |
dc.contributor.author | Li Y.-S. | en_US |
dc.contributor.author | Lee Y.-H. | en_US |
dc.contributor.author | Chen H.-M. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.creator | Yu-Yun Shao;Lin H.;Li Y.-S.;Lee Y.-H.;Chen H.-M.;Cheng A.-L.;Hsu C.-H. | - |
dc.date.accessioned | 2020-04-10T12:15:57Z | - |
dc.date.available | 2020-04-10T12:15:57Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030658698&doi=10.1093%2fjjco%2fhyx103&partnerID=40&md5=3af4990d13f8932337f8898c368c21e1 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/484060 | - |
dc.description.abstract | Purpose: Antiangiogenic therapy is crucial for advanced hepatocellular carcinoma (HCC) treatment. Interleukin (IL)-6 is an inflammatory response mediator that can promote angiogenesis. We explored its prognostic role in patients with advanced HCC. Methods: We had two patient cohorts, both comprising patients who received sorafenib-containing therapy as the first-line treatment for advanced HCC. We explored the best cut point for pretreatment plasma IL-6 levels in the exploration cohort and then confirmed it in the validation cohort. Results: In total, 55 and 73 patients constituted the exploration and validation cohorts, respectively. In the exploration cohort, a cut point of 4.28 pg/ml was the best for defining high and low IL- 6 levels because it could most effectively differentiate overall survival (OS). On application of this cut point to the validation cohort, patients with high plasma IL-6 levels, compared with patients with low IL-6 levels, exhibited significantly poorer OS (median, 8.0 vs 13.9 months, P = 0.031) but similar progression-free survival or treatment response. After adjusting for patient demographics and tumor characteristics, a high plasma IL-6 level remained an independent predictor of poor OS (hazard ratio 2.594, P = 0.005). Conclusion: High pretreatment plasma IL-6 levels were associated with poor prognosis of patients with advanced HCC. ? The Author 2017. Published by Oxford University Press. All rights reserved. | - |
dc.publisher | Oxford University Press | - |
dc.relation.ispartof | Japanese Journal of Clinical Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | interleukin 6; sorafenib; carbanilamide derivative; interleukin 6; nicotinamide; protein kinase inhibitor; sorafenib; adult; advanced cancer; aged; Article; cancer prognosis; cohort analysis; controlled study; drug response; female; human; liver cell carcinoma; major clinical study; male; overall survival; prediction; progression free survival; prospective study; protein blood level; receiver operating characteristic; sensitivity and specificity; analogs and derivatives; blood; disease free survival; genetics; liver cell carcinoma; liver tumor; middle aged; prognosis; very elderly; young adult; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Humans; Interleukin-6; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Young Adult | - |
dc.title | High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1093/jjco/hyx103 | - |
dc.identifier.pmid | 28981732 | - |
dc.identifier.scopus | 2-s2.0-85030658698 | - |
dc.relation.pages | 949-953 | - |
dc.relation.journalvolume | 47 | - |
dc.relation.journalissue | 10 | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。